{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:52:24Z","timestamp":1781646744944,"version":"3.54.5"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005639","name":"Universidade De S\u00e3o Paulo","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005639","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To evaluate the real-world efficacy and safety of temozolomide (TMZ) in aggressive and metastatic pituitary neuroendocrine tumors in a Latin American setting, and to address whether TMZ achieves meaningful radiological and biochemical disease control with acceptable toxicity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective multicenter study across Brazilian reference centers including patients with aggressive\/metastatic pituitary adenomas treated with TMZ and followed for \u2265\u20096 months. The radiological response was assessed via RECIST 1.1. For functioning pituitary adenomas, biochemical response was assessed using prespecified hormonal criteria. Adverse events were collected from medical records.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Thirty patients were included (mean age 29.5 years; 53% female). All the tumors were macroadenomas, and 56% were giant (&gt;\u20094\u00a0cm). Twenty-one pituitary adenomas were functioning and four were metastatic. Ki-67 was &gt;\u20093% in 73% of the patients. The mean time from diagnosis to TMZ initiation was 102 months. The radiological disease control rate (partial response or stable disease) was 93.3%. Among functioning tumors, the biochemical disease control rate was 81.2%, with an objective biochemical response rate (complete\u2009+\u2009partial response) of 68.8%. Adverse events, most commonly nausea and myelotoxicity, occurred in 66% of patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this multicenter Brazilian real-world cohort, TMZ provided high radiological and biochemical disease control with an acceptable safety profile, suggesting that TMZ is the preferred first-line systemic chemotherapy for aggressive\/metastatic pituitary adenomas after the failure of standard therapies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11102-026-01663-z","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T05:36:35Z","timestamp":1774589795000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Temozolomide in aggressive and metastatic pituitary tumors: a Brazilian multicenter real-world cohort study"],"prefix":"10.1007","volume":"29","author":[{"given":"Isabelle Pinheiro Amaro","family":"de Magalh\u00e3es","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camila Regina Pereira Batista","family":"de Macedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciana Ansaneli","family":"Naves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro Antonio","family":"Czepielewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella Naves","family":"Rosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidiana Bandeira","family":"de Santana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias Skrebsky","family":"de Almeida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Padula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula Cond\u00e9 Lamparelli","family":"Elias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"de Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leandro","family":"Kasuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica Roberto","family":"Gadelha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina Garcia Soares Le\u00e3es","family":"Rech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heraldo Mendes","family":"Garmes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesar Luiz","family":"Boguszewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel Soares","family":"Jallad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marilena","family":"Nakaguma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Candida Barisson Villares","family":"Fragoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcio Carlos","family":"Machado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Glezer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malebranche Berardo Carneiro","family":"da Cunha Neto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olavo","family":"Feher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5461-0301","authenticated-orcid":false,"given":"Rafael Loch","family":"Batista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,27]]},"reference":[{"key":"1663_CR1","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1056\/NEJMra1810772","volume":"382","author":"S Melmed","year":"2020","unstructured":"Melmed S (2020) Pituitary-tumor endocrinopathies. N Engl J Med 382:937\u2013950","journal-title":"N Engl J Med"},{"key":"1663_CR2","doi-asserted-by":"publisher","first-page":"R45","DOI":"10.1093\/ejendo\/lvaf100","volume":"192","author":"G Raverot","year":"2025","unstructured":"Raverot G, Burman P, Abreu AP et al (2025) Revised European Society of Endocrinology Clinical Practice Guideline for the management of aggressive pituitary tumours and pituitary carcinomas. Eur J Endocrinol 192:R45\u2013R78","journal-title":"Eur J Endocrinol"},{"key":"1663_CR3","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s11154-020-09556-7","volume":"21","author":"OM Dekkers","year":"2020","unstructured":"Dekkers OM, Karavitaki N, Pereira AM (2020) The epidemiology of aggressive pituitary tumors (and its challenges). Rev Endocr Metab Disord 21:209\u2013212","journal-title":"Rev Endocr Metab Disord"},{"key":"1663_CR4","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s11154-019-09531-x","volume":"21","author":"L Kasuki","year":"2020","unstructured":"Kasuki L, Raverot G (2020) Definition and diagnosis of aggressive pituitary tumors. Rev Endocr Metab Disord 21:203\u2013208","journal-title":"Rev Endocr Metab Disord"},{"key":"1663_CR5","first-page":"i17","volume":"7","author":"F Calvanese","year":"2025","unstructured":"Calvanese F, Jannelli G, Feuvret L et al (2025) Aggressive pituitary tumors and pituitary carcinomas: Definition, management, and overview for clinical practice. Neurooncol Adv 7:i17\u2013i28","journal-title":"Neurooncol Adv"},{"key":"1663_CR6","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EJE-17-0796","volume":"178","author":"G Raverot","year":"2018","unstructured":"Raverot G, Burman P, McCormack A et al (2018) European Society of Endocrinology clinical practice guidelines for the management of aggressive pituitary tumours and carcinomas. Eur J Endocrinol 178:G1\u2013G24","journal-title":"Eur J Endocrinol"},{"key":"1663_CR7","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-024-02836-5","volume":"148","author":"J Jotanovic","year":"2024","unstructured":"Jotanovic J, Boldt HB, Burton M et al (2024) Genome-wide methylation profiling differentiates benign from aggressive and metastatic pituitary neuroendocrine tumors. Acta Neuropathol 148:68","journal-title":"Acta Neuropathol"},{"key":"1663_CR8","doi-asserted-by":"publisher","DOI":"10.1111\/bpa.13302","volume":"35","author":"O Casar-Borota","year":"2025","unstructured":"Casar-Borota O, Burman P, Lopes MB (2025) The 2022 WHO classification of tumors of the pituitary gland: an update on aggressive and metastatic pituitary neuroendocrine tumors. Brain Pathol 35:e13302","journal-title":"Brain Pathol"},{"key":"1663_CR9","doi-asserted-by":"crossref","unstructured":"Reilly -, O\u2019, Newlands SM, Glaser ES et al (1993) Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours. Eur J Cancer 29:940\u2013942","DOI":"10.1016\/S0959-8049(05)80198-4"},{"key":"1663_CR10","doi-asserted-by":"publisher","first-page":"R545","DOI":"10.1530\/ERC-19-0083","volume":"26","author":"BC Whitelaw","year":"2019","unstructured":"Whitelaw BC (2019) How and when to use temozolomide to treat aggressive pituitary tumours. Endocr Relat Cancer 26:R545\u2013R552","journal-title":"Endocr Relat Cancer"},{"key":"1663_CR11","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1111\/j.1365-2265.2012.04381.x","volume":"76","author":"G Raverot","year":"2012","unstructured":"Raverot G, Castinetti F, Jouanneau E et al (2012) Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of temozolomide treatment. Clin Endocrinol (Oxf) 76:769\u2013775","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1663_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2018.00318","author":"LV Syro","year":"2018","unstructured":"Syro LV, Rotondo F, Camargo M et al (2018) Temozolomide and pituitary tumors: current understanding, unresolved issues, and future directions. Front Endocrinol (Lausanne). https:\/\/doi.org\/10.3389\/fendo.2018.00318","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1663_CR13","doi-asserted-by":"publisher","first-page":"1204206","DOI":"10.3389\/fendo.2023.1204206","volume":"14","author":"C Lamas","year":"2023","unstructured":"Lamas C, C\u00e1mara R, Fajardo C et al (2023) Efficacy and safety of temozolomide in the treatment of aggressive pituitary neuroendocrine tumours in Spain. Front Endocrinol (Lausanne) 14:1204206","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1663_CR14","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1111\/j.1365-2265.2008.03487.x","volume":"71","author":"AI McCormack","year":"2009","unstructured":"McCormack AI, McDonald KL, Gill AJ et al (2009) Low O6-methylguanine-DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours. Clin Endocrinol (Oxf) 71:226\u2013233","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1663_CR15","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1002\/cncr.25413","volume":"117","author":"LV Syro","year":"2011","unstructured":"Syro LV, Ortiz LD, Scheithauer BW et al (2011) Treatment of pituitary neoplasms with temozolomide. Cancer 117:454\u2013462","journal-title":"Cancer"},{"key":"1663_CR16","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s42000-019-00145-1","volume":"18","author":"G Kontogeorgos","year":"2019","unstructured":"Kontogeorgos G, Thodou E (2019) Is MGMT the best marker to predict response of temozolomide in aggressive pituitary tumors? Alternative markers and prospective treatment modalities. Horm (Athens) 18:333\u2013337","journal-title":"Horm (Athens)"},{"key":"1663_CR17","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1080\/17446651.2023.2185221","volume":"18","author":"M Padovan","year":"2023","unstructured":"Padovan M, Cerretti G, Caccese M et al (2023) Knowing when to discontinue Temozolomide therapy in responding aggressive pituitary tumors and carcinomas: a systematic review and Padua (Italy) case series. Expert Rev Endocrinol Metab 18:181\u2013198","journal-title":"Expert Rev Endocrinol Metab"},{"key":"1663_CR18","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s11060-015-1991-y","volume":"126","author":"M Losa","year":"2016","unstructured":"Losa M, Bogazzi F, Cannavo S et al (2016) Temozolomide therapy in patients with aggressive pituitary adenomas or carcinomas. J Neurooncol 126:519\u2013525","journal-title":"J Neurooncol"},{"key":"1663_CR19","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1530\/EJE-16-0979","volume":"176","author":"H Lasolle","year":"2017","unstructured":"Lasolle H, Cortet C, Castinetti F et al (2017) Temozolomide treatment can improve overall survival in aggressive pituitary tumors and pituitary carcinomas. Eur J Endocrinol 176:769\u2013777","journal-title":"Eur J Endocrinol"},{"key":"1663_CR20","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgz211","author":"U Elbelt","year":"2020","unstructured":"Elbelt U, Schlaffer SM, Buchfelder M et al (2020) Efficacy of temozolomide therapy in patients with aggressive pituitary adenomas and carcinomas-a German survey. J Clin Endocrinol Metab. https:\/\/doi.org\/10.1210\/clinem\/dgz211","journal-title":"J Clin Endocrinol Metab"},{"key":"1663_CR21","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1530\/EJE-17-0933","volume":"178","author":"A McCormack","year":"2018","unstructured":"McCormack A, Dekkers OM, Petersenn S et al (2018) Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016. Eur J Endocrinol 178:265\u2013276","journal-title":"Eur J Endocrinol"},{"key":"1663_CR22","doi-asserted-by":"publisher","first-page":"4592","DOI":"10.1210\/jc.2010-0644","volume":"95","author":"G Raverot","year":"2010","unstructured":"Raverot G, Sturm N, de Fraipont F et al (2010) Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience. J Clin Endocrinol Metab 95:4592\u20134599","journal-title":"J Clin Endocrinol Metab"},{"key":"1663_CR23","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.trecan.2017.02.002","volume":"3","author":"BC \u00d6zdemir","year":"2017","unstructured":"\u00d6zdemir BC, Dotto G-P (2017) Racial differences in cancer susceptibility and survival: more than the color of the skin? Trends Cancer 3:181\u2013197","journal-title":"Trends Cancer"},{"key":"1663_CR24","doi-asserted-by":"publisher","first-page":"9993","DOI":"10.1038\/s41467-024-54444-2","volume":"15","author":"S Li","year":"2024","unstructured":"Li S, He Y, Liu J et al (2024) An umbrella review of socioeconomic status and cancer. Nat Commun 15:9993","journal-title":"Nat Commun"},{"key":"1663_CR25","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ad.2019.05.009","volume":"112","author":"A Freites-Martinez","year":"2021","unstructured":"Freites-Martinez A, Santana N, Arias-Santiago S, Viera A (2021) Using the common terminology criteria for adverse events (CTCAE - version 5.0) to evaluate the severity of adverse events of anticancer therapies. Actas Dermosifiliogr (Engl Ed) 112:90\u201392","journal-title":"Actas Dermosifiliogr (Engl Ed)"},{"key":"1663_CR26","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/s11102-025-01541-0","volume":"28","author":"ABR Cardoso","year":"2025","unstructured":"Cardoso ABR, Zimmermann AC, Raverot G, Nunes-Nogueira VDS (2025) Effect of antineoplastic drug therapies on carcinoma and aggressive pituitary tumors: a systematic review and meta-analysis. Pituitary 28:70","journal-title":"Pituitary"},{"key":"1663_CR27","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.eprac.2024.10.008","volume":"31","author":"X Liu","year":"2025","unstructured":"Liu X, Dai C, Tian C et al (2025) Temozolomide Therapy in Management of Refractory Pituitary Adenomas: A Case Series of 39 Patients. Endocr Pract 31:42\u201351","journal-title":"Endocr Pract"},{"key":"1663_CR28","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s11102-020-01040-4","volume":"23","author":"L Lizzul","year":"2020","unstructured":"Lizzul L, Lombardi G, Barbot M et al (2020) Long-course temozolomide in aggressive pituitary adenoma: real-life experience in two tertiary care centers and review of the literature. Pituitary 23:359\u2013366","journal-title":"Pituitary"},{"key":"1663_CR29","doi-asserted-by":"publisher","first-page":"e376","DOI":"10.1016\/j.wneu.2023.09.076","volume":"180","author":"MC Findlay","year":"2023","unstructured":"Findlay MC, Drexler R, Azab M et al (2023) Crooke cell adenoma confers poorer endocrinological outcomes compared with corticotroph adenoma: results of a multicenter, international analysis. World Neurosurg 180:e376\u2013e391","journal-title":"World Neurosurg"},{"key":"1663_CR30","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-23-0021","author":"C Villa","year":"2023","unstructured":"Villa C, Baussart B, Assi\u00e9 G et al (2023) The World Health Organization classifications of pituitary neuroendocrine tumours: a clinico-pathological appraisal. Endocr Relat Cancer 30. https:\/\/doi.org\/10.1530\/ERC-23-0021","journal-title":"Endocr Relat Cancer 30"},{"key":"1663_CR31","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s00401-013-1084-y","volume":"126","author":"J Trouillas","year":"2013","unstructured":"Trouillas J, Roy P, Sturm N et al (2013) A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case-control study of 410 patients with 8 years post-operative follow-up. Acta Neuropathol 126:123\u2013135","journal-title":"Acta Neuropathol"},{"key":"1663_CR32","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/s41574-021-00550-w","volume":"17","author":"G Raverot","year":"2021","unstructured":"Raverot G, Ilie MD, Lasolle H et al (2021) Aggressive pituitary tumours and pituitary carcinomas. Nat Rev Endocrinol 17:671\u2013684","journal-title":"Nat Rev Endocrinol"},{"key":"1663_CR33","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1007\/s11102-019-00993-5","volume":"22","author":"G Kontogeorgos","year":"2019","unstructured":"Kontogeorgos G, Thodou E, Koutourousiou M et al (2019) MGMT immunohistochemistry in pituitary tumors: controversies with clinical implications. Pituitary 22:614\u2013619","journal-title":"Pituitary"},{"key":"1663_CR34","doi-asserted-by":"publisher","first-page":"700007","DOI":"10.3389\/fneur.2021.700007","volume":"12","author":"M Luo","year":"2021","unstructured":"Luo M, Tan Y, Chen W et al (2021) Clinical Efficacy of Temozolomide and Its Predictors in Aggressive Pituitary Tumors and Pituitary Carcinomas: A Systematic Review and Meta-Analysis. Front Neurol 12:700007","journal-title":"Front Neurol"},{"key":"1663_CR35","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1530\/EJE-22-0440","volume":"187","author":"P Burman","year":"2022","unstructured":"Burman P, Trouillas J, Losa M et al (2022) Aggressive pituitary tumours and carcinomas, characteristics and management of 171 patients. Eur J Endocrinol 187:593\u2013605","journal-title":"Eur J Endocrinol"},{"key":"1663_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.725014","volume":"12","author":"O Cooper","year":"2021","unstructured":"Cooper O, Bonert V, Liu N-A, Mamelak AN (2021) Treatment of aggressive pituitary adenomas: a case-based narrative review. Front Endocrinol (Lausanne) 12:725014","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1663_CR37","doi-asserted-by":"publisher","first-page":"968692","DOI":"10.3389\/fendo.2022.968692","volume":"13","author":"S Du Four","year":"2022","unstructured":"Du Four S, Van Der Veken J, Duerinck J et al (2022) Pituitary carcinoma - case series and review of the literature. Front Endocrinol (Lausanne) 13:968692","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1663_CR38","first-page":"64","volume":"5","author":"JT Jordan","year":"2018","unstructured":"Jordan JT, Miller JJ, Cushing T et al (2018) Temozolomide therapy for aggressive functioning pituitary adenomas refractory to surgery and radiation: a case series. Neurooncol Pract 5:64\u201368","journal-title":"Neurooncol Pract"},{"key":"1663_CR39","doi-asserted-by":"publisher","first-page":"E447","DOI":"10.1227\/NEU.0000000000000251","volume":"74","author":"BE Zacharia","year":"2014","unstructured":"Zacharia BE, Gulati AP, Bruce JN et al (2014) High response rates and prolonged survival in patients with corticotroph pituitary tumors and refractory Cushing disease from capecitabine and temozolomide (CAPTEM): a case series. Neurosurgery 74:E447\u2013E455 discussion E455","journal-title":"Neurosurgery"},{"key":"1663_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.558593","volume":"11","author":"G Zheng","year":"2020","unstructured":"Zheng G, Lu L, Zhu H et al (2020) Clinical, laboratory, and treatment profiles of silent corticotroph adenomas that have transformed to the functional type: a case series with a literature review. Front Endocrinol (Lausanne) 11:558593","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1663_CR41","doi-asserted-by":"publisher","first-page":"774686","DOI":"10.3389\/fendo.2021.774686","volume":"12","author":"L Das","year":"2021","unstructured":"Das L, Gupta N, Dutta P et al (2021) Early Initiation of Temozolomide Therapy May Improve Response in Aggressive Pituitary Adenomas. Front Endocrinol (Lausanne) 12:774686","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1663_CR42","doi-asserted-by":"publisher","DOI":"10.1159\/000543427","author":"C Deng","year":"2025","unstructured":"Deng C, Yang S, Pu C et al (2025) Temozolomide treatment in refractory pituitary adenomas and pituitary carcinomas. Neuroendocrinology. https:\/\/doi.org\/10.1159\/000543427","journal-title":"Neuroendocrinology"},{"key":"1663_CR43","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1097\/COC.0000000000000505","volume":"42","author":"RL Batista","year":"2019","unstructured":"Batista RL, Musolino NRC, Cescato VAS et al (2019) Cabergoline in the Management of Residual Nonfunctioning Pituitary Adenoma: A Single-Center, Open-Label, 2-Year Randomized Clinical Trial. Am J Clin Oncol 42:221\u2013227","journal-title":"Am J Clin Oncol"},{"key":"1663_CR44","first-page":"506","volume":"66","author":"G Vargas-Ortega","year":"2022","unstructured":"Vargas-Ortega G, Gonz\u00e1lez-Virla B, Balc\u00e1zar-Hern\u00e1ndez L et al (2022) Efficacy of cabergoline therapy in patients with non-functioning pituitary adenomas: A single center clinical experience. Arch Endocrinol Metab 66:506\u2013511","journal-title":"Arch Endocrinol Metab"},{"key":"1663_CR45","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s11102-023-01365-w","volume":"27","author":"I Ayalon-Dangur","year":"2024","unstructured":"Ayalon-Dangur I, Turjeman A, Hirsch D et al (2024) Cabergoline treatment for surgery-na\u00efve non-functioning pituitary macroadenomas. Pituitary 27:52\u201360","journal-title":"Pituitary"},{"key":"1663_CR46","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1530\/EJE-16-0206","volume":"175","author":"Y Greenman","year":"2016","unstructured":"Greenman Y, Cooper O, Yaish I et al (2016) Treatment of clinically nonfunctioning pituitary adenomas with dopamine agonists. Eur J Endocrinol 175:63\u201372","journal-title":"Eur J Endocrinol"},{"key":"1663_CR47","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1007\/s11102-023-01340-5","volume":"26","author":"AL Lin","year":"2023","unstructured":"Lin AL, Geer EB, Lala N et al (2023) The treatment of aggressive prolactinomas with everolimus. Pituitary 26:474\u2013481","journal-title":"Pituitary"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-026-01663-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11102-026-01663-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-026-01663-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:58:15Z","timestamp":1781643495000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11102-026-01663-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,27]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["1663"],"URL":"https:\/\/doi.org\/10.1007\/s11102-026-01663-z","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8428238\/v1","asserted-by":"object"}]},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,27]]},"assertion":[{"value":"22 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"63"}}